Payment overview · 2025
General Payments
$186.23
11 reported records · 9 companies
Healthcare provider profile · identity verified
John M. Krodel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORMAN, OK · NPI 1225020035
Verified facts
What the public records show
CMS Open Payments records show John M. Krodel, M.D. received $186.23 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.69 | 27.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.94 | 11.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.98 | 10.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.46 | 9.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.48 | 8.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.34 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.96 | 8.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.80 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.58 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.23 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 106 |
| Lisinopril | Lisinopril | 321 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 80 |
| Omeprazole | Omeprazole | 243 | 75 |
| Gabapentin | Gabapentin | 239 | 59 |
| Losartan Potassium | Losartan Potassium | 221 | 69 |
| Furosemide | Furosemide | 215 | 64 |
| Simvastatin | Simvastatin | 209 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 55 |
| Potassium Chloride | Potassium Chloride | 176 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 49 |
| Irbesartan | Irbesartan | 170 | 44 |
| Montelukast Sodium | Montelukast Sodium | 166 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 41 |
| Metformin Hcl | Metformin Hcl | 149 | 46 |
| Carvedilol | Carvedilol | 130 | 37 |
| Sertraline Hcl | Sertraline Hcl | 125 | 34 |
| Ozempic | Semaglutide | 123 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 30 |
| Eliquis | Apixaban | 111 | 26 |
| Celecoxib | Celecoxib | 108 | 31 |
| Atenolol | Atenolol | 107 | 29 |
| Allopurinol | Allopurinol | 104 | 26 |
| Tramadol Hcl | Tramadol Hcl | 100 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 30 |
| Trazodone Hcl | Trazodone Hcl | 93 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 27 |
| Metformin Hcl Er | Metformin Hcl | 82 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 30 |
| Prednisone | Prednisone | 77 | 51 |
| Estradiol | Estradiol | 76 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 20 |
| Meloxicam | Meloxicam | 74 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 30 |
| Clonazepam | Clonazepam | 70 | 12 |
| Famotidine | Famotidine | 68 | 25 |
| Synthroid | Levothyroxine Sodium | 68 | 15 |
| Bupropion Xl | Bupropion Hcl | 67 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 67 | 18 |
| Finasteride | Finasteride | 63 | 18 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 58 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 15 |
| Lorazepam | Lorazepam | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 13 |
| Donepezil Hcl | Donepezil Hcl | 53 | 15 |
| Spironolactone | Spironolactone | 53 | 14 |
| Glipizide | Glipizide | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | 12 |
| Cephalexin | Cephalexin | 48 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 14 |
| Mirtazapine | Mirtazapine | 46 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 13 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 19 |
| Temazepam | Temazepam | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Diazepam | Diazepam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Valsartan | Valsartan | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Naproxen | Naproxen | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.23 · 11 records | PFIZER INC. | ABRYSVO, AREXVY, BEYFORTUS, COMIRNATY, CONTRAVE, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, INSPIRE, MENQUADFI, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, UNITHROID, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error